Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate Injection Site Safety in Schizophrenia
NCT00119756Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2005
- Modality
- Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, sponsored by Johnson & Johnson. Started Jun 2005; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00119756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00119756.